Impact of the BioFire® BCID2 panel on antimicrobial treatment and mortality in pediatric gram-negative bloodstream infections
Diagnostic Microbiology and Infectious Disease, cilt.113, sa.3, 2025 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 113 Sayı: 3
- Basım Tarihi: 2025
- Doi Numarası: 10.1016/j.diagmicrobio.2025.117003
- Dergi Adı: Diagnostic Microbiology and Infectious Disease
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, Environment Index, MEDLINE
- Anahtar Kelimeler: BioFire (R) BCID2 Panel, Antimicrobial stewardship, Gram-negative Bloodstream Infections, Mortality, Treatment
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: Rapid molecular diagnostics, such as the BioFire® BCID2 Panel, may improve clinical outcomes by facilitating earlier pathogen identification and antimicrobial stewardship. This study evaluates the impact of BCID2 implementation on antimicrobial treatment and mortality in pediatric Gram-negative Bloodstream infections (BSI). Methods: Pediatric patients with microbiologically confirmed Gram-negative BSI were divided into two groups: the pre-BCID2 group (diagnosed using conventional blood cultures) and the BCID2 group (diagnosed using the BCID2 Panel). Primary outcomes included time to pathogen identification and antimicrobial treatment modifications. Secondary outcomes included 7-day and 30-day mortality rates. Results: A total of 97 Gram-negative BSI episodes were analyzed (pre-BCID2: 59, BCID2: 38). The BCID2 panel significantly reduced the time to appropriate antimicrobial therapy (median reduction: 55.1 h, p < 0.01). Antimicrobial treatment was modified in 78.9 % of cases following BCID2 results, with 42.1 % requiring changes due to resistance gene detection. Glycopeptide use was discontinued in 28.9 %. The 7-day mortality rate was 10.5 % in the BCID2 group versus 8.5 % in the pre-BCID2 group (p > 0.05). Conclusions: The BCID2 panel significantly accelerated pathogen and resistance gene identification, leading to improved appropriate antimicrobial usage in pediatric Gram-negative BSI.